DMT210

DMT210 is a topical small molecule drug developed as a novel anti-inflammatory therapy for dermatological conditions, particularly atopic dermatitis and acne rosacea. It is based on a new chemical entity from the isoprenylcysteine class, designed as a structural mimic of the amino acid tail at the C-terminus of G-proteins. DMT210 acts as a G-protein coupled receptor (GPCR) modulator and inhibits multiple proinflammatory cytokines, including interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNF-α). The drug works by blocking TLR2 and GPCR signaling pathways in the skin, thereby reducing inflammation and erythema associated with these diseases. Clinical studies have shown that DMT210 has minimal systemic exposure when applied topically, an acceptable safety profile, and efficacy in reducing both inflammatory lesions and redness in patients with moderate to severe acne rosacea[1][2][3][5][7].

Other names

dmt210dmt-210dmt 210